Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Enrolled subjects were histologically confirmed resectable stage II, IIIA, and IIIB NSCLC (according to the 9th edition AJCC Lung Cancer TNM Staging System), with no evidence of distant metastasis and no evidence of unresectable local regional tumor extension.